According to population based analyses, oncologic patients might have a higher risk of develop COVID-19 and poorer outcomes compared to individuals without cancer .

In this report we describe the case of a non small cell lung cancer (NSCLC) patient undergoing chemo-immunotherapy who developed COVID-19 pneumonia. He was treated with tocilizumab and significantly improved after the first dose. Non acute side effects were observed.

More data on patients undergoing (chemo)immunotherapy affected by COVID-19 are needed to draw definitive conclusions. However the clinical outcome of this patient suggest that tocilizumab can be safely used to treat COVID-19 pneumonia in patients undergoing (chemo)immunotherapy.

Introduction {#sec1}
============

Since December 2019, the outbreak of a novel coronavirus, SARS-CoV-2, infection (COVID-19) has spread worldwide \[[@bib1]\]. The number of confirmed cases has reached 16,536,862 including 654,247 deaths, as of July 27th, 2020 \[[@bib2]\].

The case fatality rate (number of deaths in persons who tested positive for SARS-CoV-2 divided by number of SARS-CoV-2 cases) is higher for the elderly and those with underlying comorbidites, such as diabetes, chronic respiratory disease, cardiovascular disease as well as cancer \[[@bib3], [@bib4], [@bib5]\].

Growing evidence suggests that SARS-CoV-2 infection may induce an aberrant host immune response associated with a "cytokine storm syndrome" characterized by massive release of pro-inflammatory cytokines, including IL-6, and associated with worse prognosis \[[@bib6], [@bib7]\].

Tocilizumab is a recombinant humanized monoclonal antibody directed against IL-6 receptor. It is approved by EMA for the treatment of rheumatoid arthritis, systemic juvenile idiopathic arthritis, and of chimeric antigen receptor (CAR) T cell-induced cytokine release syndrome \[[@bib8]\]. Additionally has shown efficacy in the treatment of steroid refractory immune related adverse events (irAEs) \[[@bib9], [@bib10]\].

Limited data are available on critically ill patients treated with tocilizumab for COVID-19 pneumonia . In a prospective series of 100 consecutive patients admitted to the Spedali Civili University Hospital in Brescia (Italy) with COVID-19 pneumonia and respiratory failure requiring ventilatory support, treatment with tocilizumab was associated with a clinical benefit in more than three quarters of patients \[[@bib11]\]. However although other observational studies suggest that tocilizumab may be associated with better outcomes compared to standard care in patients with severe COVID-19 , randomized clinica trials with larger sample size are required confirm this hypotesis \[[@bib12]\]. Information in cancer patients is scarce.

We report our experience with tocilizumab in a patient affected stage IV lung adenocarcinoma, who developed COVID-19 pneumonia after the first cycle of chemoimmunotherapy.

Case report {#sec1.1}
-----------

The patient, a 65 years old man without major comorbidities and Eastern Cooperative Oncology Group (ECOG) performance status 1, former smoker (15 packs year), was diagnosed with stage IV lung adenocarcinoma (bilateral lung metastases) in February 2020. He received vaccination for seasonal flu. Based on radiological staging and molecular profile (PDL1 2%, absence of ALK and ROS translocations, and of EGFR and BRAF mutations), he started treatment with carboplatin, pemetrexed and pembrolizumab on March 6th. On March 13th (day 1), he presented to our outpatient clinic reporting fever in the last 24 hours and productive cough. On initial physical examination he was tachycardic (100 bpm) and febrile (40 C) with fine crackles on the right lung base. The ratio of arterial oxygen partial pressure to fractional inspired oxygen (PO2/Fi02 ratio) in room air was 328. Blood tests showed grade 3 leucopenia and neutropenia and elevation of C reactive protein (CRP) ([table 1](#tbl1){ref-type="table"} ). Chest X ray did not demonstrate any signs of interstitial pneumonia. A nasopharyngeal SWAB for COVID 19 was performed. The patient was hospitalized and treatment with granulocyte colony stimulating factors (G-CSFs) and large spectrum empiric antibiotics was started. No steroids were administered. Results of RT-PCR testing for C-19 nucleic acid were positive on day 2 (24 hours after admission). As per hospital protocol darunavir 800 mg/die, ritonavir 100 mg/die, hydroxychloroquine 200 mg bid were prescribed. Despite ongoing therapy and oxygen supplementation with reservoir mask at 15 L/min, clinical conditions did not improve. CRP increased to 225 mg/l; Interleukin 6 levels, tested for the first time, were 101 ng/l ([table 1](#tbl1){ref-type="table"}). Blood cultures, legionella and pneumococcal urinary antigen tests, performed on admission, were negative. P/F ratio dropped to 58 on day 7. CT scan showed areas of consolidation in right and left lower lobes with diffuse ground glass opacities and inter and intra lobular septal thickening (crazy paving) ([fig 1a](#fig1){ref-type="fig"} ). On day 8 and 9 the patient was given the first and second dose of tocilizumab (8 mg per Kg of weight every 12 hours) with immediate benefit. P/F ratio went up to 100 the morning after the first dose and in the following days oxygen support was gradually decreased. CPR dropped down from 212 mg/dl to 37 mg/dl 48 hours after the second dose. ([table 1](#tbl1){ref-type="table"}).Table 1Laboratory valuesReference rangeDAY 1DAY 4DAY 7DAY 8DAY\
9DAY\
9DAY 11DAY 18WBC count x 103/mm33.90-10.601.611.5814.81I\
DOSE\
OF TCZ5730II\
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CT scan performed after administration of demonstrated a reduction of the ground glass opacities([fig 1b](#fig1){ref-type="fig"}). Lung tumour was stable. The patient was discharged with P/F ratio of 370 (room air) on day 13. After a second CT scan confirmed a further improvement of GGOs the patient resumed chemo-immunotherapy without complications.

Conclusion {#sec2}
==========

Short term treatment with tocilizumab proved to be safe in this patient undergoing chemoimmunotherapy for stage IV lung adenocarcinoma.

According to population based analyses, oncologic patients, especially lung cancer ones, might have a higher risk of developing COVID-19 and of poorer outcomes compared to individuals without cancer \[[@bib3], [@bib13], [@bib14], [@bib15]\].

In the era of long term survivors treated with immune checkpoint inhibitors (ICIs) and target therapies, generalisations should be avoided. The immunological status of a patient undergoing immunotherapy is different from that of one treated with chemotherapy or target therapy.

Immunotherapy may act as a double edged sword. On one side patients undergoing immunotherapy may be more immunocompetent than those receiving chemotherapy and therefore be less at risk of developing COVID 19 related complications. On the other hand ICIs related immune hyper-activation could promote the onset of the above-mentioned "cytokine storm syndrome"\[[@bib16]\]. The association of ICIs with chemotherapy (like in the reported case) further complicates the scenario.

Furthermore, the potential overlap of COVID-19 pneumonia and ICIs associated lung damage represents another source of concern.

In both situations a predominant role is played by the release of cytokines including IL6 \[[@bib6], [@bib17]\]. By blocking the IL6 receptor, tocilizumab can disrupt this cascade of events and restore the functionality of the alveoli.

The present report has several limitations: first the patient received concomitant therapies both for febrile neutropenia and for COVID 19 (antivirals and hydroxychloroquine). Second monitoring of all inflammatory indexes was not performed, although CRP could be considered a good surrogate of IL6 \[[@bib17]\]. Third long term outcomes are not yet available. Nevertheless the timeline of events suggest a potential efficacy of tocilizumab.

More data and longer follow up are needed on cancer patients undergoing immunotherapy (plus or minus chemotherapy) affected by COVID 19 to draw definitive conclusions. However the clinical outcome of this patient suggests that tocilizumab can be safely used to treat COVID-19 pneumonia in patients treated with ICIs.
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Clinical practice points

COVID-19 has spread worldwide. Currently no vaccines or drugs have been approved for its treatment**.**
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[^1]: WBC count: White blood cell count ; CPR C reactive protein; IL6 interleukin 6 ; LDH Lactate dehydrogenase, TCZ : tocilizumab
